These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 17092250)

  • 21. Monitoring minimal residual disease using chromosomal translocations in childhood ALL.
    Cazzaniga G; Rossi V; Biondi A
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):21-35. PubMed ID: 11987914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
    Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
    Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Detection of minimal residual disease in acute leukemias by flow cytometry].
    Scolnik MP
    Medicina (B Aires); 2000; 60 Suppl 2():83-6. PubMed ID: 11188938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.
    Cazzaniga G; Biondi A
    Haematologica; 2005 Mar; 90(3):382-90. PubMed ID: 15749670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges.
    Izraeli S; Waldman D
    Acta Haematol; 2004; 112(1-2):34-9. PubMed ID: 15179003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Jiang LM; Zhao JC; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):246-50. PubMed ID: 19374803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits of minimal residual disease negativity in the therapy of chronic lymphocytic leukemia.
    Kay NE
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):727-9. PubMed ID: 18997661
    [No Abstract]   [Full Text] [Related]  

  • 29. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of detection of minimal residual disease.
    Wörmann B
    Curr Opin Oncol; 1993 Jan; 5(1):3-12. PubMed ID: 8427891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow-cytometric detection of minimal residual disease in adult acute lymphoblastic leukemia.
    Krampera M; Perbellini O; Maggioni A; Scognamiglio F; Todeschini G; Pizzolo G
    Haematologica; 2001 Mar; 86(3):322-3. PubMed ID: 11255283
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL.
    Goulden N; Steward C
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):59-70. PubMed ID: 11987916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group.
    Krejci O; van der Velden VH; Bader P; Kreyenberg H; Goulden N; Hancock J; Schilham MW; Lankester A; Révész T; Klingebiel T; van Dongen JJ
    Bone Marrow Transplant; 2003 Oct; 32(8):849-51. PubMed ID: 14520434
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
    Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
    Borowitz MJ; Pullen DJ; Winick N; Martin PL; Bowman WP; Camitta B
    Cytometry B Clin Cytom; 2005 Nov; 68(1):18-24. PubMed ID: 16184615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications.
    Roberts WM; Zipf TF; Kitchingman GR; Tubergen DG; Estrov Z
    Cytokines Mol Ther; 1995 Mar; 1(1):65-9. PubMed ID: 9384665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.
    Pedreira CE; Costa ES; Almeida J; Fernandez C; Quijano S; Flores J; Barrena S; Lecrevisse Q; Van Dongen JJ; Orfao A;
    Cytometry A; 2008 Dec; 73A(12):1141-50. PubMed ID: 18836994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
    Ryan J; Quinn F; Meunier A; Boublikova L; Crampe M; Tewari P; O'Marcaigh A; Stallings R; Neat M; O'Meara A; Breatnach F; McCann S; Browne P; Smith O; Lawler M
    Br J Haematol; 2009 Jan; 144(1):107-15. PubMed ID: 19016726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.